Everything else is secondary
MAUD-obesity trial: Patients with obesity, no T2D, and markers of more severe AUD, comparing newer GLP-1 RAs to MAUD
Yoshinori Abe advises, "GLP-1 users should track body composition, waist size, strength, and metabolic labs rather than weight or BMI alone, since BMI cannot show fat versus muscle." Pay attention to your physical strength as well
Research Use Only Notice: Retatrutide is a research peptide intended for in-vitro and animal research applications only
Data on the on-medication state for MDS-UPDRS Part III were available from four studies
The results, which were published in the Lancet on Thursday, are very encouraging for the safety and efficacy of orforglipron in people with type 2 diabetes, says Daniel Drucker, an endocrinologist at the University of Toronto, adding that he is awaiting further clinical trial results of the drug in people with obesity